Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK1GBJ)

Drug Name
Trazodone Drug Info
Synonyms
Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Therapeutic Class
Antidepressants
Cross-matching ID
PubChem CID
5533
ChEBI ID
CHEBI:9654
CAS Number
CAS 19794-93-5
TTD Drug ID
DMK1GBJ
VARIDT Drug ID
DR00490
INTEDE Drug ID
DR1631
ACDINA Drug ID
D00698

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [11]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [12]
Fluoxetine DM3PD2C Bipolar depression Approved [2]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [13]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [14]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [15]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [16]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [2]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [2]
Paroxetine DM5PVQE Anxiety disorder 6B00-6B0Z Approved [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [17]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [18]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [19]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [13]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [20]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [21]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [22]
Treximet DMU54QB Migraine 8A80 Approved [23]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [24]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [26]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [27]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [28]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [29]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [30]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [31]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [32]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [33]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [27]
Verapamil DMA7PEW Angina pectoris BA40 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [35]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [36]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [37]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [30]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [34]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [38]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [39]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [40]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [41]
Propranolol DM79NTF Angina pectoris BA40 Approved [42]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [55]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [56]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [57]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [58]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [59]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [60]
Capsaicin DMGMF6V Back pain ME84.Z Approved [61]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [62]
Quinidine DMLPICK N. A. N. A. Approved [63]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [64]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [43]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [44]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [45]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [5]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [47]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [48]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [49]
Verapamil DMA7PEW Angina pectoris BA40 Approved [50]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [51]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [5]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [5]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [5]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [52]
Verapamil DMA7PEW Angina pectoris BA40 Approved [53]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [5]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [5]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [5]
Metronidazole DMTIVEN Abscess Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 1A (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [6]
Fluoxetine DM3PD2C Bipolar depression Approved [65]
Methamphetamine DMPM4SK Anxiety Approved [66]
Olanzapine DMPFN6Y Bipolar depression Approved [67]
Perospirone DMVHJLX Psychotic disorder 6A20-6A25 Approved [67]
Etoperidone DMR7U8F N. A. N. A. Phase 4 [6]
phorbol 12-myristate 13-acetate DMJWD62 Acute myeloid leukaemia 2A60 Phase 2 [68]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [69]
DU 125530 DM63UA9 Mood disorder 6A60-6E23 Discontinued in Phase 2 [70]
THAPSIGARGIN DMDMQIE N. A. N. A. Preclinical [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [7]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [7]
Fluoxetine DM3PD2C Bipolar depression Approved [7]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [71]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [72]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [73]
Testosterone DM7HUNW Hot flushes GA30 Approved [74]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [75]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [76]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [77]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Proepiregulin (EREG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [78]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [79]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [80]
Quercetin DM3NC4M Obesity 5B81 Approved [81]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [82]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [83]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-1 alpha (IL1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [84]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [8]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [85]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [86]
Quercetin DM3NC4M Obesity 5B81 Approved [87]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [88]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-1 beta (IL1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [90]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [91]
Gefitinib DM15F0X Colon adenocarcinoma Approved [92]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [93]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [94]
Selenium DM25CGV N. A. N. A. Approved [95]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [96]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [97]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Antileukoproteinase (SLPI)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [8]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [79]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [89]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [8]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hepatocyte growth factor receptor (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [98]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [99]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [100]
Quercetin DM3NC4M Obesity 5B81 Approved [81]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [101]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-8 (CXCL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [102]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [103]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [104]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [105]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [106]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [91]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [93]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [107]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [108]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [8]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [8]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [8]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [8]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [109]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [8]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [75]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [110]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [111]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [112]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [113]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [114]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [115]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [116]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [117]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [118]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [119]
Selenium DM25CGV N. A. N. A. Approved [95]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [82]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [120]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [121]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [8]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [8]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [8]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [122]
Quinidine DMLPICK N. A. N. A. Approved [123]
Verapamil DMA7PEW Angina pectoris BA40 Approved [124]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [125]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [125]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [126]
Propranolol DM79NTF Angina pectoris BA40 Approved [127]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [128]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [129]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [125]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-24 (IL24)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [84]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [8]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [91]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [130]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [82]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [131]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [8]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [131]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [9]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [132]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [133]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [134]
Estrone DM5T6US Acne vulgaris ED80 Approved [135]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [136]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [137]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [138]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [139]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [105]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [8]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [8]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [8]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [8]
Amikacin DM5PDRB Bacteremia 1A73 Approved [8]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [8]
Promethazine DM6I5GR Hyperemesis gravidarum Approved [8]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [8]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [76]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [140]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [141]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [100]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [142]
Quercetin DM3NC4M Obesity 5B81 Approved [81]
Fluoxetine DM3PD2C Bipolar depression Approved [143]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Modulator [2]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Modulator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [4]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [5]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 1A (HTR1A) OT38K9MK 5HT1A_HUMAN Protein Interaction/Cellular Processes [6]
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Protein Interaction/Cellular Processes [7]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [8]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [8]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Gene/Protein Processing [8]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [9]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Drug Response [10]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Gene/Protein Processing [8]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Gene/Protein Processing [8]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 213).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
4 Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
5 Drug Interactions Flockhart Table
6 Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. doi: 10.1007/BF02244985.
7 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
8 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
9 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
12 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
13 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
14 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
15 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
16 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
17 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
18 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
19 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
20 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
21 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
22 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
23 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
25 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
26 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
27 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
28 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
29 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
30 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
31 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
32 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
33 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
34 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
35 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
36 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
37 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
38 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
39 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
40 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
41 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
42 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
43 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
44 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
45 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
46 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
47 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
48 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
49 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
50 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
51 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
52 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
53 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
54 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
55 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
56 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
57 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
58 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
59 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
60 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
61 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
62 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
63 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
64 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
65 Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006 Jan-Feb;6(1):27-33. doi: 10.1038/sj.tpj.6500340.
66 Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010 Feb;58(2):452-6. doi: 10.1016/j.neuropharm.2009.09.006. Epub 2009 Sep 10.
67 Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther. 2010 May;27(5):307-13. doi: 10.1007/s12325-010-0035-4. Epub 2010 Jun 8.
68 Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. J Pharmacol Exp Ther. 2001 Jun;297(3):1025-35.
69 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
70 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002 Jun;301(3):1144-50.
71 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
72 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
73 Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
74 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
75 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
76 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
77 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
78 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
79 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
80 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
81 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
82 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
83 Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
84 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
85 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
86 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
87 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
88 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
89 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
90 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
91 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
92 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
93 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
94 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
95 Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
96 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
97 Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
98 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
99 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
100 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
101 All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
102 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
103 Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
104 Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
105 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
106 Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
107 Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
108 Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
109 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
110 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
111 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
112 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
113 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
114 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
115 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
116 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
117 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
118 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
119 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
120 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
121 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
122 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
123 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
124 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
125 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
126 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
127 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
128 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
129 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
130 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
131 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
132 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
133 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
134 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
135 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
136 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
137 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
138 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
139 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
140 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
141 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
142 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
143 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.